Published on : Mar 14, 2017
ALBANY, NY, March 14, 2017: Cervical cancer, resulting from the abnormal growth of cervical cells in the cervix, is spread via a virus called human papilloma virus (HPV). Cervical cancer is mostly caused by HPV 16 and HPV 18 virus that also result in anal cancer and penile cancer in men. On account of the rising number of cervical cancer diagnostic tests such as Pap smear tests, HPV testing, and colposcopy for early detection, the market has become highly competitive.
Pap test is the most widely used test for detection of pre-cancer stages on account of its affordability. It is followed by visual inspection with acetic acids (VIA). The HPV test is mostly carried out for screening high risk cancer cells and not much for cervical cancer detection. Such screening tests are used and conducted by various end-users such as diagnostic centers, hospitals, clinics, home care, and laboratories. Among them, the clinics segment rakes in maximum revenue and is trailed by hospitals and laboratories.
The report studies the global cervical cancer screening market, estimates its current size, and forecasts its future. At present the market is fragmented with numerous large, medium, and small sized companies competing against each other for a larger share in it. The vendors compete against each other based on pricing, product sensitivity, product differentiation, and high investments. The market is predicted to be worth US$7 bn by 2020.
Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=995379
Some of the factors leading to the growth in the global cervical cancer screening market is the rise in awareness about the malady and favorable health care policies. Countering the growth in the market is the dearth of awareness among women in less developed nations, difficulty in availing appropriate screening tests, and insufficient skilled medical staff and laboratories to carry out tests.
The report studies the market in 20 countries across the world. Some of them are Malaysia, Sweden, Australia, the U.K., the U.S., Canada, Indonesia, Norway, Germany, Korea, China, India, and France. Among them, the U.S. and Japan account for around 50 percent of the market share. Europe is another key region powered by the U.K. and France. Further, Asia, on account of India, Indonesia, and China, is home to most number of cervical cancer screening people. Studies show, Japan market will steadily decline in the years ahead.
Some of the prominent players in the global cervical cancer screening market profiled in the report are Abott Molecular, Hologic, Becton, Roche Molecular Diagnostics, Dickinson & Company, Qiagen, and Quest Diagnostics.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org